A 12-Week, Double-Blind, Placebo-Controlled Trial of Ferric Citrate for the Treatment of Iron Deficiency Anemia and Reduction of Serum Phosphate in Patients.

Slides:

Advertisements

Similar presentations

Renal Function Testing

Advertisements

Advancing Management of Anemia With the Latest Data From ERA-EDTA 2018

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:

KDOQI US Commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD Mark J. Sarnak, MD, MS, Roy Bloom, MD, Paul Muntner, PhD,

Anemia management in chronic kidney disease

American Journal of Kidney Diseases

Douglas S. Fuller, MS, Ronald L. Pisoni, PhD, MS, Brian A

Peritoneal dialysis American Journal of Kidney Diseases

Uric Acid as a Target of Therapy in CKD

Gregory L. Hundemer, MD, MPH, Andrew Z. Fenves, MD, Kristy M

Surviving the First Year of Peritoneal Dialysis: Enduring Hard Times

Kostas C. Siamopoulos, MD, FRSH, Chariklia Gouva, MD, Konstantinos P

Amir Said Alizadeh Naderi, MD, Biff F. Palmer, MD

A Decade After the KDOQI CKD Guidelines

Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A Dialysis Provider’s Perspective J. Michael Lazarus, MD, Raymond M. Hakim,

Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-

Recognition for Conservative Care in Kidney Failure

Urine Acidification After Ammonium Chloride

Evaluation of the Potential Living Kidney Donor

Focusing on Health Literacy Might Help Us Cross the Quality Chasm

Daniel E. Weiner, MD, MS American Journal of Kidney Diseases

Salt and Hypertension American Journal of Kidney Diseases

Erratum Regarding “Phosphate Removal With Several Thrice-Weekly Dialysis Methods in Overweight Hemodialysis Patients” [Am J Kidney Dis 2009; 54: ]

Augmented Nurse Care Management in CKD Stages 4 to 5: A Randomized Trial Steven Fishbane, MD, Sofia Agoritsas, MPA, Alessandro Bellucci, MD, Candice Halinski,

Effect of Fish Oil on Vitamin D Absorption

The DOPPS Practice Monitor for US Dialysis Care: Update on Trends in Anemia Management 2 Years Into the Bundle Douglas S. Fuller, MS, Ronald L. Pisoni,

Effect of Protein Restriction on Serum and Urine Phosphate in the Modification of Diet in Renal Disease (MDRD) Study Britt Newsome, MD, Joachim H. Ix,

Joseph A. Vassalotti, MD, Lesley A. Stevens, MD, MS, Andrew S

Hemoglobin Level and Transfusions in Patients on Maintenance Dialysis: Where the Rubber Meets the Road Eduardo Lacson, MD, MPH, Franklin Maddux, MD

Nosratola D. Vaziri, MD American Journal of Kidney Diseases

A Decade After the KDOQI CKD Guidelines: A Historical Perspective

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

Usability Testing and Acceptance of an Electronic Medication Inquiry System for CKD Patients Clarissa J. Diamantidis, MD, MHS, Marni Zuckerman, MA, Wanda.

Sankar D. Navaneethan, MD, MPH, Suetonia C. Palmer, MBChB, Jonathan C

Julie A. Wright Nunes, MD, MPH, Kerri L

The Map Is Not the Territory—Mapping Out the Course and Cost of CKD

Pharmacokinetics of Multiple-Dose Levofloxacin in Hemodialysis Patients Shuichi Tsuruoka, MD, PhD, Noritsugu Yokota, MD, PhD, Tokie Hayasaka, RN, Tetsuo.

Elevated Fibroblast Growth Factor 23 in a Patient With Metastatic Prostate Cancer and Hypophosphatemia Casey L. Cotant, MD, Panduranga S. Rao, MD, DNB,

A Decade After the KDOQI CKD Guidelines: A Perspective From Mexico

CPR 1.2.: Evaluation of Anemia in CKD

Plasma Parathyroid Hormone Level and Prevalent Cardiovascular Disease in CKD Stages 3 and 4: An Analysis From the Kidney Early Evaluation Program (KEEP)

Salicylate Intoxication as a Cause of Pseudohyperchloremia

Quiz Page April 2008 American Journal of Kidney Diseases

Study Designs in Patient-Oriented Research

Race/Ethnicity and Cardiovascular Outcomes in Adults With CKD: Findings From the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic CRIC Studies

Drug Dose Adjustments in Patients With Renal Impairment

Daniel T. Lackland, DrPH, David J.P. Barker, MD, PhD

Sulfamethoxazole Crystalluria

Daniel E. Weiner, MD, MS, Mark J. Sarnak, MD, MS

Risk for Incident Renal Dialysis in a Managed Care Population

Long-term Outcomes of Acute Kidney Injury: The Power and Pitfalls of Observational/Population-Based Studies Charuhas V. Thakar, MD American Journal.

Lesley A. Stevens, MD, MS, Josef Coresh, MD, PhD, Andrew S. Levey, MD

Trial Quality in Nephrology: How Are We Measuring Up?

Removal of Dabigatran by Hemodialysis

Multidrug-Resistant Organisms Within the Dialysis Population: A Potentially Preventable Perfect Storm David P. Calfee, MD, MS American Journal of Kidney.

Differences in Blood Transfusion Trends Between US and UK Centers

Kidney Failure Treatment: The Freedom to Choose

Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), Madhav V. Rao,

In the Literature: Cognitive Impairment in Hemodialysis Patients

Achieving Fairness in Access to Kidney Transplant: A Work in Progress

James F. Winchester, MD, Thomas H. Hostetter, MD, Timothy W. Meyer, MD

Quiz Page June 2011 American Journal of Kidney Diseases

Dialysis Research and N-of-1 Trials: Made for Each Other?

Quiz Page January 2010 American Journal of Kidney Diseases

Clinical Practice Recommendations For Peritoneal Dialysis Adequacy

IgA Nephropathy: A Disease in Search of a Large-Scale Clinical Trial to Reliably Inform Practice Giovanni F.M. Strippoli, MD, PhD, MPH (Hons), MM (Epi),

Clinical Practice Guidelines for Peritoneal Dialysis Adequacy

Quiz page December 2003 American Journal of Kidney Diseases

Phosphate Balance in Continuous Venovenous Hemofiltration

Medication Adherence Behavior and Priorities Among Older Adults With CKD: A Semistructured Interview Study Dena E. Rifkin, MD, MS, M. Barton Laws, PhD,

Presentation transcript:

A 12-Week, Double-Blind, Placebo-Controlled Trial of Ferric Citrate for the Treatment of Iron Deficiency Anemia and Reduction of Serum Phosphate in Patients With CKD Stages 3-5 Geoffrey A. Block, MD, Steven Fishbane, MD, Mariano Rodriguez, MD, Gerard Smits, PhD, Shay Shemesh, MS, Pablo E. Pergola, MD, Myles Wolf, MD, MMSc, Glenn M. Chertow, MD, MPH American Journal of Kidney Diseases Volume 65, Issue 5, Pages 728-736 (May 2015) DOI: 10.1053/j.ajkd.2014.10.014 Copyright © 2015 National Kidney Foundation, Inc. Terms and Conditions

Figure 1 Study design. (A) Schematic shows study drug dose adjustments made based on laboratory serum phosphate (P) results. (B) Patient disposition. American Journal of Kidney Diseases 2015 65, 728-736DOI: (10.1053/j.ajkd.2014.10.014) Copyright © 2015 National Kidney Foundation, Inc. Terms and Conditions

Figure 2 Primary and secondary iron-related end points: (A) transferrin saturation, (B) hemoglobin, and (C) ferritin values. Data represent mean (standard error [SE]) using the modified intention-to-treat treatment group. ∗P<0.05 using Wilcoxon rank sum test. American Journal of Kidney Diseases 2015 65, 728-736DOI: (10.1053/j.ajkd.2014.10.014) Copyright © 2015 National Kidney Foundation, Inc. Terms and Conditions

Figure 3 Primary and secondary phosphate-related end points: (A) serum phosphate (mg/dL), (B) urine phosphate (mg/24 h), (C) intact fibroblast growth factor 23 (FGF-23; pg/mL), and (D) carboxy-terminal FGF-23 (RU/mL). Data represent mean (standard error [SE]) or median (SE) using the modified intention-to-treat treatment group. ∗P<0.05 using Wilcoxon rank sum test. American Journal of Kidney Diseases 2015 65, 728-736DOI: (10.1053/j.ajkd.2014.10.014) Copyright © 2015 National Kidney Foundation, Inc. Terms and Conditions